FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

Implant, Dermal, For Aesthetic Use

PMA: P040024 · Supplement: S113 · Decision Jun 20, 2019
Classifications
1
FEI Numbers
29
Registration Numbers
29

Basic Information

Device Name
Implant, Dermal, For Aesthetic Use
Trade Name
RESTYLANE NASHA
PMA Number
P040024
Supplement Number
S113
Device Class
FDA Class 3
Product Code
LMH
Generic Name
Implant, dermal, for aesthetic use
Medical Specialty
Unknown
Advisory Committee
General, Plastic Surgery
Decision
30-Day Notice Accepted
Decision Code
OK30
Decision Date
June 20, 2019
Date Received
May 21, 2019
Supplement Type
30-Day Notice
Supplement Reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

Outsourcing the method of analysis for D-value determination of biological indicators produced by Galderma Uppsala, Sweden.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LMH Implant, Dermal, For Aesthetic Use